Tharimmune, Inc. Files 8-K for Material Definitive Agreement

Ticker: CNTN · Form: 8-K · Filed: Jun 20, 2025 · CIK: 1861657

Tharimmune, INC. 8-K Filing Summary
FieldDetail
CompanyTharimmune, INC. (CNTN)
Form Type8-K
Filed DateJun 20, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-definitive-agreement, corporate-action

TL;DR

Tharimmune (THAR) signed a big deal, filing an 8-K on 6/20/25.

AI Summary

On June 13, 2025, Tharimmune, Inc. entered into a Material Definitive Agreement. The company, formerly known as Hillstream BioPharma Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. The filing was made on June 20, 2025.

Why It Matters

This 8-K filing indicates a significant new agreement for Tharimmune, Inc., which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material Definitive Agreements can introduce significant new risks or opportunities, the nature of which is not detailed in this initial filing.

Key Players & Entities

FAQ

What is the nature of the Material Definitive Agreement Tharimmune, Inc. entered into?

The filing states that Tharimmune, Inc. entered into a Material Definitive Agreement on June 13, 2025, but the specific details of the agreement are not provided in this initial 8-K filing.

When was this 8-K filing submitted to the SEC?

The 8-K filing was submitted to the SEC on June 20, 2025.

What was Tharimmune, Inc.'s former company name?

Tharimmune, Inc. was formerly known as Hillstream BioPharma Inc., with a name change occurring on September 25, 2023.

In which state is Tharimmune, Inc. incorporated?

Tharimmune, Inc. is incorporated in Delaware.

What is Tharimmune, Inc.'s primary business sector?

Tharimmune, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification code 2834.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding Tharimmune, Inc. (CNTN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing